Peptide Initiative

Peptides · Peptide comparison

Chonluten vs Crystagen

Bronchopulmonary tripeptide bioregulator (Glu-Asp-Gly) that restores respiratory epithelial function through DNA minor groove binding at ATTTC sequences, induces TNF tolerance in alveolar macrophages reducing inflammatory cytokines by up to 6-fold, and normalizes bronchial mucosa differentiation markers in aging lung tissue

Immunogeroprotective tripeptide bioregulator (Glu-Asp-Pro) that optimally stimulates thymic epithelial cell proliferation at 200 ng/mL, suppresses thymocyte apoptosis through p53 downregulation and Ki-67 upregulation, and contributed to a 4.1-fold mortality reduction in a 266-person 6-8 year clinical study when combined with complementary pineal peptides

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangeChonluten5–10 mgCrystagen200–400 mcg
FrequencyChonlutenOnce dailyCrystagenOnce daily
AdministrationChonlutenSublingual (enteric-coated capsules)CrystagenSubcutaneous injection
Cycle lengthChonluten12+ weeksCrystagen8-12 weeks
Onset speedChonlutenGradual (3-4 weeks)CrystagenGradual (3-4 weeks)
Evidence levelChonlutenLimited human trialsCrystagenLimited human trials

Efficacy

Benefit ratings

Respiratory Tissue Repair

Chonluten62%
CrystagenNo recorded rating

Lung Inflammation Control

Chonluten58%
CrystagenNo recorded rating

Age-Related Lung Protection

Chonluten55%
CrystagenNo recorded rating

Immune Rejuvenation

ChonlutenNo recorded rating
Crystagen94%

Healthy Aging

ChonlutenNo recorded rating
Crystagen91%

Cancer Defense

ChonlutenNo recorded rating
Crystagen85%

Technical data

Compound specifications

Chonluten

Molecular formula
C11H17N3O8
Molecular weight
319.27 g/mol
Half-life
Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to bronchopulmonary gene expression; metabolized to constituent amino acids
Bioavailability
Absorbed via intestinal peptide transporters (PepT1) in oral formulation with enteric coating; rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short tripeptide structure
CAS number
75007-24-8

Crystagen

Molecular formula
C14H21N3O8
Molecular weight
359.3 g/mol
Half-life
Short plasma half-life typical of tripeptides (minutes); biological effects persist for weeks to months through gene expression modifications and thymic microenvironment restoration; metabolized to constituent amino acids
Bioavailability
Absorbed via intestinal peptide transporters (PepT1/POT and LAT carrier families) when administered orally; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to ultra-short tripeptide structure
CAS number
Not assigned (patented as immunogeroprotective peptide, US8057810B2)

Protocols

Dosing compared

Chonluten

Subcutaneous

  • 5-10 mgOnce daily · 10-20 days per courseFor the synthetic peptide form, a dose commonly used in research practice given as an injection under the skin. [6]

Oral

  • 1-2 capsules1-2 times daily with meals · 10-30 day course, repeated 2-3 times per yearThe oral capsule plan used in practice for this bronchopulmonary peptide supplement. [6]

Crystagen

Subcutaneous

  • 200-400 mcgOnce daily · 10-20 days per course, repeated every 4-6 monthsFor the synthetic peptide form, a dose commonly used in research practice given as an injection under the skin. [6]

Intramuscular

  • 200-400 mcgOnce daily · 10-20 days per course, repeated every 4-6 monthsCan also be given as an intramuscular injection at a similar dose, used in research practice. [6]

Oral

  • 1-2 capsules (10 mg each)1-2 times daily with meals · 10-30 day course, repeated every 4-6 monthsThe oral capsule plan used in practice. Each Cytogen capsule holds 10 mg, delivering about 200-400 mcg of active peptide per dose. [6]

Applications

Best suited for

Chonluten

Respiratory health restoration in aging individuals with declining lung function
Chonluten is particularly well-suited for individuals focused on respiratory health restoration in aging individuals with declining lung function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic bronchopulmonary conditions requiring tissue-level regenerative support
Chonluten is particularly well-suited for individuals focused on chronic bronchopulmonary conditions requiring tissue-level regenerative support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function
Chonluten is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting respiratory and immune function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy for lung tissue preservation in elderly populations
Chonluten is particularly well-suited for individuals focused on geroprotective therapy for lung tissue preservation in elderly populations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Crystagen

Restoring thymic function and immune competence in aging individuals with immune senescence
Crystagen is particularly well-suited for individuals focused on restoring thymic function and immune competence in aging individuals with immune senescence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols for immune and anti-aging support
Crystagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for immune and anti-aging support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting immune function during and after illness recovery
Crystagen is particularly well-suited for individuals focused on supporting immune function during and after illness recovery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence
Crystagen is particularly well-suited for individuals focused on geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Chonluten

Common

  • Injection site reaction
  • Mild fatigue
  • Transient respiratory changes
  • Mild headache

Uncommon

  • Flu-like symptoms

Serious

  • No documented serious adverse effects

Crystagen

Common

  • Injection site reaction
  • Mild fatigue
  • Mild headache
  • Minor digestive changes

Uncommon

  • Flu-like symptoms

Serious

  • No documented serious adverse effects

Research status

Safety & evidence

Chonluten

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Chonluten is a cartilage-derived peptide extract used primarily in Russian and Eastern European medicine that lacks FDA approval and rigorous clinical safety data. As a poorly defined mixture of collagen peptides and proteoglycans from cartilage tissue, standardization and batch consistency cannot be guaranteed. Potential risks include allergic reactions to connective tissue proteins, contamination from animal tissues, and unknown immunological effects from proteoglycan components. No formal safety assessments, animal toxicology studies by modern standards, or human Phase 1/2 trials exist. Long-term safety outcomes are completely unstudied.

Contraindications

  • Known hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, glycine)
  • Pregnancy and breastfeeding — insufficient reproductive safety data
  • Active pulmonary infections requiring immediate medical treatment
  • Severe immunosuppression without medical supervision — immunomodulatory effects may be unpredictable

Crystagen

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature. As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects. No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available.

Contraindications

  • Known hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, proline)
  • Pregnancy and breastfeeding — insufficient reproductive safety data
  • Active autoimmune disease in flare without physician supervision
  • Organ transplant recipients on immunosuppression — potential interference with immunosuppressive regimens

Decision guide

Which is right for you?

Chonluten

Choose Chonluten if…

  • Respiratory health restoration in aging individuals with declining lung function
  • Chronic bronchopulmonary conditions requiring tissue-level regenerative support
  • Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function
  • Geroprotective therapy for lung tissue preservation in elderly populations

Crystagen

Choose Crystagen if…

  • Restoring thymic function and immune competence in aging individuals with immune senescence
  • Comprehensive Khavinson bioregulator protocols for immune and anti-aging support
  • Supporting immune function during and after illness recovery
  • Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence